CME/CE from MPR


MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for myCME.com. See below for a list of each quarter's courses. Click here to visit MPR's website.




Latest Courses

Clinical Review

New Drug Review from MPR (April 2014)

1.00 Credits
Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits
HM 



Archived CME/CE Courses

HM 


MPR Drug News


Tainted Sexual Supplement Contains Hidden Ingredient

The FDA is warning consumers not to purchase or use O.M.G., a product marketed for sexual enhancement.

New Genetic Links to Schizophrenia Discovered

Researchers have unmasked 108 chromosomal sites harboring inherited variations in the genetic code linked to schizophrenia, of which 83 have never been reported before in the largest genomic dragnet of any psychiatric disorder to date.

FDA Accepts sBLA, Grants Priority Review for Avastin in Ovarian Cancer

The FDA grants Genentech's sBLA for Avastin (bevacizumab) plus chemotherapy Priority Review for the treatment of women with recurrent platinum-resistant ovarian cancer.

First Lots of Fluzone Shipped for 2014-2015 Flu Season

Sanofi Pasteur has announced that the first lots of Fluzone (Influenza vaccine) for the 2014-2015 season have been shipped.

Status Epilepticus Therapy Granted Fast Track Status

The FDA has designated Fast Track status to SAGE-547 (SAGE Therapeutics) for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens.